The global burden of chronic urticaria for the patient and society*

DOI HANDLE HANDLE Web Site Web Site ほか1件をすべて表示 一部だけ表示 被引用文献4件
  • M. Gonçalo
    Department of Dermatology University Hospital and Faculty of MedicineUniversity of Coimbra Coimbra Portugal
  • A. Gimenéz‐Arnau
    Department of Dermatology Hospital del MarIMIMUniversitat Autònoma Barcelona Spain
  • M. Al‐Ahmad
    Microbiology Department Faculty of Medicine Kuwait University Kuwait
  • M. Ben‐Shoshan
    Division of Allergy, Immunology and Dermatology Department of Pediatrics Montreal Children’s HospitalMcGill University Montréal QC Canada
  • J.A. Bernstein
    University of Cincinnati College of MedicineDepartment of Internal Medicine, Division of Immunology/Allergy Section, Partner Bernstein Allergy Group and Bernstein Clinical Research Center Cincinnati OH USA
  • L.F. Ensina
    Alergoalpha/CPAlpha Allergy Clinic and Clinical Research Center and Division of Allergy, Clinical Immunology and Rheumatology Department of Pediatrics Federal University of São Paulo (UNIFESP/EPM) São Paulo SP Brazil
  • D. Fomina
    Moscow City Center of Allergy and Immunology Clinical City Hospital #52 Department of General Therapy Pirogov Russian National Research Medical University Moscow Russian Federation
  • C.A. Galvàn
    Instituto Nacional de Salud del NiñoCentro de Referencia Nacional de Alergia Asma e Inmunología, Lima Perú
  • K. Godse
    Department of Dermatology Dr D.Y. Patil School of Medicine Mumbai Maharashtra India
  • C. Grattan
    St John’s Institute of DermatologyGuy’s Hospital London UK
  • M. Hide
    Department of Dermatology Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
  • C.H. Katelaris
    Campbelltown Hospital and Western Sydney University Sydney NSW Australia
  • M. Khoshkhui
    Allergy Research Center Mashhad University of Medical Sciences Mashhad Iran
  • E. Kocatürk
    Department of Dermatology Koc University School of Medicine Istanbul Turkey
  • K. Kulthanan
    Department of Dermatology Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
  • I. Medina
    Centro Medico VitaeDepartment of Allergy and Clinical Immunology Buenos Aires Argentina
  • I. Nasr
    Department of Immunology and Allergy Royal Hospital Muscat Oman
  • J. Peter
    Division of Allergy and Clinical Immunology University of Cape Town and Allergy and Immunology UnitUniversity of Cape Town Lung Institute Cape Town South Africa
  • P. Staubach
    Department of Dermatology University Medical Center Mainz Mainz Germany
  • L. Wang
    Liangchun Wang – Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
  • K. Weller
    Dermatological Allergology Allergie‐Centrum‐Charité Department of Dermatology and Allergy Charité – Universitätsmedizin Berlin Berlin Germany
  • M. Maurer
    Dermatological Allergology Allergie‐Centrum‐Charité Department of Dermatology and Allergy Charité – Universitätsmedizin Berlin Berlin Germany

書誌事項

公開日
2020-11-02
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
  • http://doi.wiley.com/10.1002/tdm_license_1.1
DOI
  • 10.1111/bjd.19561
公開者
Oxford University Press (OUP)

この論文をさがす

説明

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.

収録刊行物

被引用文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ